期刊
CHEMPHOTOCHEM
卷 5, 期 5, 页码 421-425出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cptc.202000283
关键词
excited states; photodynamic therapy; ruthenium; singlet oxygen; TLD1433; triplet states
资金
- German Science Foundation [395358570]
- Carl Zeiss Foundation
- National Cancer Institute (NCI) of the National Institutes of Health (NIH) [R01CA222227]
The study of TLD1433, the first Ru(II) complex tested as a photodynamic therapy agent in a clinical trial, reveals that increasing oligothiophene chain length changes its photophysical properties, especially impacting the generation of O-1(2) and its potential as a photocytotoxic agent, with the addition of a third thiophene playing a critical role.
TLD1433 is the first Ru(II) complex to be tested as a photodynamic therapy agent in a clinical trial. In this contribution we study TLD1433 in the context of structurally-related Ru(II)-imidozo[4,5-f][1,10]phenanthroline (ip) complexes appended with thiophene rings to decipher the unique photophysical properties which are associated with increasing oligothiophene chain length. Substitution of the ip ligand with ter- or quaterthiophene changes the nature of the long-lived triplet state from metal-to-ligand charge-transfer to (3)pi pi* character. The addition of the third thiophene thus presents a critical juncture which not only determines the photophysics of the complex but most importantly its capacity for O-1(2) generation and hence the potential of the complex to be used as a photocytotoxic agent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据